A one‑year course of T‑DM1 offers excellent cancer‑free survival for early HER2‑positive breast cancer, with far less nerve ...

Precision Biologics, Inc. CEO Philip M. Arlen, MD, discusses discovery and development of tumor-specific monoclonal antibodies (mAb) in "Discovery and Development of Monoclonal Antibodies Targeting ...

Researchers led by teams at NYU Langone Health and its Perlmutter Cancer Center have reported on the development of antibodies that can selectively target cancer-related mutations in the extracellular ...

SAN FRANCISCO -- Perioperative sacituzumab govitecan (Trodelvy) and pembrolizumab (Keytruda) achieved a "promising" clinical ...

BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate ...

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other ...

Illustration of a new form of precision medicine, an antibody, with the potential to treat several types of cancer. Researchers have managed to combine three different functions in the antibody, which ...

Cancer scientists engineer a new type of antibody which could be used to boost the immune systems of patients fighting disease. Cancer scientists say they have engineered a new type of super-strong ...